Managed a US healthcare, biotech, tech and volatility portfolio: - Biotech M&A highlights: CPXX (307% return), MDVN (111% return), FMI (129% return), ARRY (562% return)

- Develop C-H functionalization strategies in monosaccharides for the expedient synthesis of L-glucose- Established site-selective radical methodologies to furnish bench-stable halogenated monosaccharides- Supervise an undergraduate researcher to further derivatize the aforementioned halogenated compounds- Conduct mechanistic studies and utilize insights to guide reaction optimization

Managed a US long/short healthcare portfolio:- Delivered a 24.2% return in 2015 vs -0.7% in S&P 500- Diversified portfolio via multiple strategies: fundamental analysis, patent analysis and - Conducted thorough fundamental research by attending management meetings and scientific conferences- Created and maintained models for healthcare companies to support fundamental analysis

Bottom up fundamental analysis: - Study the pipeline of a company - Evaluate the efficacy of its drugs by understanding the mechanism of action. - Value companies through real options analysis, risk-adjusted NPV and/or comparable analysis - Evaluate sentiment through comparing buy side vs sell side expectationsTypes of trades: - Long/short equity and derivatives - Long term investments in undervalued names - Event driven trades: IND applications, clinical trials, NDA/BLA, adcom, PDUFA - Secondary offerings

PhD Classes Taught: - BIOL 1270/2270: Advanced BiochemistryUndergraduate Classes Taught: - CHEM 0100: Introductory Chemistry - CHEM 0330: Equilibrium, Rate, and Structure - CHEM 0350: Organic Chemistry I - CHEM 0360: Organic Chemistry II - BIOL 0500: Cell and Molecular Biology

Organic Chemistry Synthesis:Synthetic Methodologies and Applications of Functional Isocyanide

Molecular Biology Research:Study of Sir2 and p53 genes' connection to longevity in Drosophila

Sales and Trading

Stem Cell Research:Sterochemistry of Panax Notoginseng and its Effect on Angiogenesis